Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination With Lenalidomide Versus Rituximab in Combination With Lenalidomide Therapy in Relapsed/Refractory Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5). The study aims to evaluate the safety and efficacy of odronextamab combined with lenalidomide compared to the current standard treatment of rituximab with lenalidomide in patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma.
The intervention being tested is odronextamab, an experimental drug administered via intravenous infusion, combined with lenalidomide, an oral medication. This combination is being compared to rituximab, administered either intravenously or subcutaneously, with lenalidomide.
The study employs a randomized, parallel intervention model without masking, focusing on treatment as its primary purpose. It consists of two parts: Part 1 assesses safety and dosage, while Part 2 compares the efficacy of the two treatment combinations.
The study began on December 28, 2023, and is currently recruiting participants. The primary completion date is expected to be in June 2025, with the last update submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and potential impact on treatment standards.
This clinical trial update could influence Regeneron’s stock performance and investor sentiment, as successful results might enhance the company’s market position in the oncology sector. The trial’s outcome could also affect competitors offering similar treatments for non-Hodgkin’s lymphoma.
The study is ongoing, with further details available on the ClinicalTrials portal.